Free Pulmonology CME 2017‑2018 | CMEList.com

 


Hot Topics in the Management of Idiopathic Pulmonary Fibrosis
Free Pulmonolgy CME Posted by...Bernard Sklar, MD.
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Pulmonologists and other health care professionals involved in the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Educational material last updated...December 31, 2016.
CME Credit Expires...December 31, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc.
Hot Topics in the Management of Idiopathic Pulmonary Fibrosis consists of three brief video presentations about idiopathic pulmonary fibrosis (IPF).
Upon successful completion of Hot Topics in the Management of Idiopathic Pulmonary Fibrosis, you should be better able to:
• Assess recent clinical advances regarding the use of available and emerging therapies for the management of IPF.
• Implement treatment strategies that reflect the most recent clinical data regarding the treatment of IPF.

An Update on Fixed-Dose LAMA/LABA Inhalers in COPD
Posted by...Bernard Sklar, MD. Free Lung Cancer CME
Free Pulmonology CME Credit hours...2.0.
CME Credits Awarded by....The France Foundation
Cost...........Free.
Instruction Type...Text-and-Graphics.
Target Audiences...This program is intended for health care professionals who treat and manage patients with COPD.
Educational material updated....September 30, 2016.
Expiration of CME credit...September 29, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc.
An Update on Fixed-Dose LAMA/LABA Inhalers in COPD consists of written presentations by 4 experts on the use of Fixed-Dose Inhalers in COPD
Upon completion of An Update on Fixed-Dose LAMA/LABA Inhalers in COPD, you should be able to:
• Evaluate key efficacy data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Evaluate key safety data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Apply information on the efficacy and safety of new/emerging LAMA/LABA inhalers in COPD to specific clinical scenarios.

High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy Free Lung Cancer CME
Posted by...Bernard Sklar, MD.
Free Pulmonology CME Credit hours...0.5. 
CME Credits Awarded by....The France Foundation
Cost...........Free.
Instruction Type...Slide-Video Lecture.
Target Audiences...This program is intended for pulmonologists, critical care clinicians and other healthcare professionals involved in the management of patients with NSCLC.
Educational material updated....November 18, 2016.
Expiration of CME credit...November 17, 2017.
Financial Support...Bristol-Myers Squibb.
Dr. Momen Wahidi and Dr. W. Dean Wallace discuss how molecular diagnostics and targeted therapy rely on adequate tissue biopsy.
Upon completion of High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy, you should be able to:
• Identify key aspects of current guidance pertaining to adequate tissue acquisition and its implications in NSCLC
• Recognize the importance of obtaining adequate tissue samples for NSCLC diagnosis and classification, including molecular analysis

Work-Up of a Patient with Right Upper Lobe Mass and Metastases Free Lung Cancer CME
Posted by...Bernard Sklar, MD.
Free Pulmonology CME Credit hours...0.5. 
CME Credits Awarded by....The France Foundation.
Cost...........Free.
Instruction Type...Slide-Video Lecture.
Target Audiences...This program is intended for pulmonologists, critical care clinicians and other healthcare professionals involved in the management of patients with NSCLC.
Educational material updated....November 18, 2016.
Expiration of CME credit...November 17, 2017.
Financial Support...Bristol-Myers Squibb.
W. Dean Wallace, MD and Dr. Momen Wahidi discuss tissue processing and analysis from the pathology perspective.
Upon completion of Work-Up of a Patient with Right Upper Lobe Mass and Metastases, you should be able to:
• Identify key aspects of current guidance pertaining to adequate tissue acquisition and its implications in NSCLC
• Recognize the importance of obtaining adequate tissue samples for NSCLC diagnosis and classification, including molecular analysis

Lung Immunotherapies: Shifting the Lung Cancer Treatment Paradigm
Live online November 3, 2016, and available on demand through May 3, 2017.
Posted by...Bernard Sklar, MD.Lung Cancer CME
Free Oncology CME Credit hours...1.0. 
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for medical oncologists, oncology nurses, nurse practitioners, physician assistants, primary care physicians, pulmonologists, and others involved and/or interested in the therapeutic management of patients with lung cancer.
Educational material updated... November 3, 2016.
Expiration of CME credit...May 3, 2017.
Financial Support...Merck.
After viewing Lung Immunotherapies: Shifting the Lung Cancer Treatment Paradigm, you will be better able to:
• Summarize the underlying principles for immunotherapeutic strategies taking into consideration lung cancer pathophysiology.
• Evaluate the safety and efficacy of available and emerging immunotherapies
• Determine if or when immunotherapy is appropriate in the first- and second-line settings for patients with metastatic NSCLC
• Address adverse events associated with immunotherapy in lung cancer

Updates in Lung Cancer: Targeting Epidermal Growth Factor Receptor
Live online September 7, 2016, and available on demand through March 7, 2017.
Posted by...Bernard Sklar, MD.Lung Cancer CME
Free Lung Cancer CME Credit hours...1.0.
CME Credits Awarded by....Albert Einstein College of Medicine.
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for oncologists, oncology nurses, nurse practitioners, physician assistants, internists, primary care physicians, pulmonologists, and other health care professionals who treat patients with lung cancer.
Educational material updated... September 7, 2016.
Expiration of CME credit... March 7, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc.
Updates in Lung Cancer: Targeting Epidermal Growth Factor Receptor consists of a single lecture:
• Updates in Lung Cancer: Targeting Epidermal Growth Factor Receptor
At the conclusion of Updates in Lung Cancer, you will be able to:
• Review the pathophysiology of NSCLC and the role played by EGFR and activating EGFR mutations
• Provide the rationale for EGFR mutation testing to identify appropriate patients for targeted therapy
• Evaluate currently approved EGFR inhibitors and their role in the treatment of NSCLC
• Discuss the adverse events common to this drug class and how individual drugs might differ, and present management strategies

Updates in Lung Cancer: ALK Inhibition in the Treatment of NSCLC Free Pulmonary CME
Live online September 7, 2016, and available on demand through March 7, 2017.
Posted by...Bernard Sklar, MD.
Free Oncology CME Credit hours...1.0.
CME Credits Awarded by....Albert Einstein College of Medicine
Cost...........Free.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for medical oncologists, radiation oncologists, lung surgeons, fellows and other health care professionals (primary care physicians, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with lung cancer.
Educational material updated...September 7, 2016.
Expiration of CME credit... March 7, 2017.
Financial Support...Ariad Pharmaceuticals, Inc.
At the conclusion of Updates in Lung Cancer: ALK Inhibition in the Treatment of NSCLC, you will be able to:
• Provide rationale for testing for ALK mutations and use of ALK inhibitors
• Evaluate latest clinical data on new and emerging ALK inhibitors and combinations for use in patients with NSCLC
• Manage resistance to ALK inhibitors with appropriate second-line options